<DOC>
	<DOCNO>NCT01272531</DOCNO>
	<brief_summary>This prospective pharmacogenomics study mood stabilizer response . The goal work identify gene associate good response patient bipolar disorder two commonly use mood stabilize agent , lithium valproate .</brief_summary>
	<brief_title>Pharmacogenomics Mood Stabilizer Response Bipolar Disorder ( PGBD )</brief_title>
	<detailed_description>All subject meeting study inclusion criterion start lithium . Those fail lithium cross valproate ( VPA ) . Those also fail VPA crossed-over standardized treatment usual ( TAU ) arm . Subjects eligible study must least 18 year age diagnose thought bipolar I disorder least one episode mood instability last 12 month . They must also eligible take lithium , female child bearing age , agree use adequate birth control method inform doctor plan become pregnant .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Genetic Diseases , X-Linked</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<criteria>Any phase bipolar I disorder include , depressive , manic , hypomanic , mixed , baseline/euthymic/not symptomatic ; Lithium na√Øve patient inadequately past lithium treat patient require least one affective episode last 12 month meet DSMIV criterion . Current lithium treat patient ( CLTPs ) stable lithium monotherapy exempt criterion mood episode meeting DSMIV criterion last 6 month ; Both outpatient inpatient permit enroll study ; Able give inform consent , judgment investigator ; Age great equal 18 year ; Women child bear potential agree inform doctor early possible time plan conceive , use adequate contraception ( e.g . oral contraceptive , intrauterine device , barrier method , total abstinence intercourse ) , understand risk lithium fetus infant . Depo Provera acceptable start 3 month prior enrollment . Unwilling unable comply study requirement ; Renal impairment ( serum creatinine &gt; 1.5 mg/dL ) ; Thyroid stimulate hormone ( TSH ) &gt; 20 % upper normal limit ( participant maintain thyroid medication must euthyroid least 3 month Visit 1 ; Other contraindication lithium ; Currently crisis inpatient hospitalization crisis management take priority ; Subjects alcohol/drug dependence meet criterion physical dependence require acute detoxification ; Pregnant breastfeeding ; Women childbearing potential n't able agree requirement specify ; Those participate clinical trial investigational drug within past 1 month ; Inability agree comply visit schedule study procedure ; History lithium toxicity , due mismanagement overdose required treatment ; Current unstable medical condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>pharmacogenetics</keyword>
	<keyword>bipolar disorder</keyword>
	<keyword>affective disorder</keyword>
	<keyword>mood disorder</keyword>
	<keyword>pharmacologic action</keyword>
	<keyword>psychotropic drug</keyword>
	<keyword>antimanic agent</keyword>
	<keyword>antidepressant agent</keyword>
	<keyword>lithium</keyword>
	<keyword>lithium carbonate</keyword>
	<keyword>Lithobid</keyword>
	<keyword>Eskalith</keyword>
	<keyword>divalproex</keyword>
	<keyword>divalproex sodium</keyword>
	<keyword>Depakote</keyword>
	<keyword>valproate</keyword>
</DOC>